Healthy
Conditions
Keywords
Healthy
Brief summary
This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.
Detailed description
In this study, the investigators aim to investigate the effect of various lipid types on GLP-2 and GLP-1 secretion. This will allow to determine the importance of lipids in nutritional solutions. Moreover, this will allow us to assess whether existing clinical formulas can be improved in order to stimulate GLP-2 and accelerate intestinal recovery.
Interventions
DIETARY_SUPPLEMENTmeal intake
Intake of meals characterized by lipid composition
DIETARY_SUPPLEMENTPlacebo
Sponsors
Société des Produits Nestlé (SPN)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* BMI : 19 - 24.9 kg.m-2 * Normal fasting glycemia * Having obtained his informed consent.
Exclusion criteria
* Gastro-intestinal disease (ulcer), pancreatic disease, hepatic disease, metabolic diseases / disorders (diabetes, dyslipidemia), renal disease, cardiovascular disease (arterial hypertension), as determined by the medical screening visit and a blood analysis. * Have had a gastrointestinal surgery (with the exception of appendices resection). * Malabsorption disorders * Lactose intolerance * Significant weight loss during the past three months (more than 5% of initial weight) * Have a regular consumption of medication * Regular supplements (vitamins and minerals) intake during the previous month * Have an alcohol intake: \> 2 units a day * Smoker (more than 2 cigarettes a day) * Illicit substances intake, as stated on the medical screening questionnaire * Allergy to any food or medication * Anaemia defined by a number of erythrocytes or hemoglobin Hb or hematocrit Ht which are inferior to laboratory normal ranges * Having given blood in the past three months or willing to give blood in the 3 months following the completion of the study * Intense physical activity \> 3 hours per week * Currently participating or having participated in another clinical trial during the past month. * Volunteer who cannot be expected to comply with the protocol, including consuming rapidly the study products, chronic medication intake
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GLP-2 and GLP-1 kinetics | changes from baseline to 4 hours following meal intake | GLP-2 and GLP-1 are measured using Elisa |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intestinal and metabolic hormones | Changes from baseline to 4 hours following meal intake | Those hormones will be measured based on enzymatic technics |
Countries
Switzerland
Outcome results
None listed